NMT Capital Team

Greg has over 27 years of venture capital investment experience, having played a leadership role in the management of a number of venture capital funds. He currently represents Nexus on the Boards of Aethon, Kiyatec and Zipit Wireless. Greg also represented Nexus as a director of Sabal Medical and Cutanea Life Sciences until he negotiated their sale to a European and Asian acquirer respectively. In the past, he has been an active Board member of both public and private corporations, providing assistance and guidance on issues associated with business strategy, corporate expansion, organizational development, and becoming successful publicly traded companies. Selected investments include Biodel (novel insulin formulation, IPO), PerSeptive Biosystems (protein separation systems, acquired by Perkin Elmer) and Infusion Systems (disposable IV pump, acquired by Baxter). Prior to joining Nexus, Greg was a general partner of Prince Ventures, a healthcare- focused, venture capital partnership. During the 1980s, Greg was Vice President and Special Limited Partner of the Vista Group where he worked closely with Ed Snape, the leader of Vista's health care practice, and Bob Fleming, Vista's IT partner. From 1972 until 1979, Greg was an executive with Baxter Laboratories. His three member team was responsible for bringing CAPD (Continuous Ambulatory Peritoneal Dialysis) into Baxter, where it became the second-most profitable product line in the company, then accounting for approximately 20% of Baxter's total profits. Greg received a BS in aerospace and mechanical engineering from Princeton University; an MS in mechanical engineering the Massachusetts Institute of Technology (MIT); and an MS from MIT's Sloan School of Management.